SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Cullinan reports anti-leukemic activity in Phase 1 CLN-049 study

Valid market news retained in the public archive without immediate LiveCast distribution.

CGEM

Related stories